![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Lymphatic mapping and sentinel lymph node biopsy (SLNB) have emerged as a promising minimally invasive surgical technique to detect metastatic nodes in patients with melanoma and breast, colon, esophageal, gastric, lung, head and neck, and thyroid cancers. The SLNB procedure is safe and feasible, with high accuracy in predicting occult metastases of differentiated thyroid cancer. The sensitivity of the SLNB technique has increased as technical details and complementary immunohistochemical and molecular techniques have been developed. SLNB for thyroid cancer may display practical benefits in accurate nodal staging, the detection of metastatic lymph nodes outside the central neck, and the selection of patients who would benefit from complete neck dissection and optimized 131I ablation therapy. Currently, however, there is no direct evidence that SLNB is associated with long-term clinical and survival benefits in patients with thyroid cancer. Well-controlled prospective clinical trials will determine the clinical significance of occult metastases and their early detection by SLNB in patients with thyroid cancer.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.